Fortis Healthcare shares have suffered a sharp correction over 34% after climbing to around ₹1,100 in October 2025, and over 25% in 3 months, but the decline could be setting up a potential technical rebound.
Choice Equity Broking's Sumeet Bagadia sees buying interest emerging near a crucial support zone around ₹750, with the stock's technical indicators suggesting that selling pressure may be approaching an extreme.
Choice has recommended buying Fortis shares at ₹794, with a target price of ₹892 and a stop-loss at ₹745.
“After peaking around ₹1,100 in late 2025, the stock underwent a significant correction and has now approached a crucial horizontal demand zone of ₹750. This zone presents an important support base for stabilization and a potential recovery towards higher levels.” Choice Equity Broking said in its research report.
The healthcare stock declined around 2% to hit its 52-week low of ₹723.40 today. It is now down over 34% from its 52-week high of ₹1,101.40, hit in October last year.